Difficulty: Intermediate | Prerequisites: Chemical Messengers study notes (Part 1), basic enzyme function
Tags: signal transduction, receptors, GPCRs, G protein-coupled receptors, second messengers, cAMP, ion channels, tyrosine kinase, up-regulation, down-regulation, agonist, antagonist, signal amplification
Once a chemical messenger reaches its target cell, something has to happen inside the cell for the message to take effect. That "something" is signal transduction: the conversion of an extracellular signal into an intracellular response. This topic covers the receptor types that detect messengers, the intracellular cascades they trigger, how cells tune their sensitivity, and how the nervous and endocrine systems use these pathways differently. You should already be comfortable with the chemical classes of messengers and the distinction between lipophilic and hydrophilic molecules (covered in Part 1).
Receptors sit either on the cell membrane (for hydrophilic messengers) or inside the cell (for lipophilic messengers). Membrane receptors come in three main flavours: channel-linked, enzyme-linked, and G protein-coupled (GPCRs). GPCRs are the most abundant and use second messengers like cAMP to amplify signals massively. Cells regulate their own sensitivity by adjusting receptor numbers (up-regulation and down-regulation).
Signal transduction
The process by which a messenger binding a receptor triggers a cascade of intracellular events that produce a cellular response. In simple terms, the chain of events between "signal arrives" and "cell does something."
Receptor
A protein that specifically binds a particular messenger (ligand), initiating a cellular response. Think of it as a lock that only the right key can open.
Specificity (receptor)
The property by which a receptor binds only certain ligands and not others, based on molecular shape and charge.
Affinity (receptor)
How tightly a receptor binds its ligand. High-affinity receptors respond to very low concentrations of messenger.
Up-regulation
An increase in the number of receptors on a cell surface, typically in response to prolonged low levels of messenger. The cell becomes more sensitive.
Down-regulation
A decrease in the number of receptors, typically in response to prolonged high levels of messenger. The cell becomes less sensitive. In simple terms, the cell turns down the volume when the signal is too loud.
Agonist
A molecule that binds a receptor and activates it, mimicking the natural ligand's effect.
Antagonist
A molecule that binds a receptor but does not activate it, blocking the natural ligand from binding. Think of it as a key that fits the lock but will not turn.
G protein-coupled receptor (GPCR)
A membrane receptor with seven transmembrane domains that activates intracellular G proteins when a ligand binds. The most common receptor type in the body.
G protein
An intracellular signalling protein that acts as a molecular switch, cycling between active (GTP-bound) and inactive (GDP-bound) states. Subtypes include Gs (stimulatory), Gi (inhibitory), and Gq.
Second messenger
A small intracellular molecule (e.g. cAMP, DAG, IP3, Ca²⁺) produced in response to receptor activation that relays and amplifies the signal inside the cell. The first messenger is the extracellular ligand.
cAMP (cyclic adenosine monophosphate)
A widely used second messenger produced from ATP by the enzyme adenylate cyclase. Broken down by phosphodiesterase.
Phosphodiesterase (PDE)
The enzyme that degrades cAMP, terminating the signal. Caffeine inhibits PDE, which is why it prolongs cAMP signalling and increases alertness.
Tyrosine kinase receptor
An enzyme-linked membrane receptor that, upon ligand binding, phosphorylates tyrosine residues on itself and downstream proteins, activating signalling cascades.
Ligand-gated ion channel (channel-linked receptor)
A membrane receptor that opens an ion channel directly upon ligand binding, allowing rapid changes in membrane potential.
Intracellular receptor
A receptor located in the cytosol or nucleus that binds lipophilic messengers. The hormone-receptor complex typically acts as a transcription factor.
Hormone response element (HRE)
A specific DNA sequence where a hormone-receptor complex binds to regulate gene transcription.
Signal amplification
The process by which a single messenger-receptor event generates a large intracellular response through cascading activation of enzymes and second messengers.
When a messenger binds its receptor, the cell may respond in several ways:
Changes in enzyme activity (activation or inhibition).
Altered gene expression (more or less of a specific protein).
Opening or closing of ion channels.
Changes in cell metabolism or overall function.
The type of response depends on the receptor class and the intracellular pathway it activates.
Specificity: each receptor binds a particular set of ligands. A cell only responds to a messenger if it expresses the right receptor.
Affinity: high-affinity receptors can detect very low messenger concentrations; low-affinity receptors require higher concentrations to respond.
Multiple receptor types: a single target cell can express several different receptor types, allowing it to respond to multiple messengers with nuanced, layered regulation.
Cells are not passive. They adjust their sensitivity to ongoing signals.
Up-regulation: when messenger levels are chronically low, the cell inserts more receptors into its membrane, becoming more sensitive. This is partly why drug withdrawal can cause rebound effects: receptors have up-regulated during chronic exposure, so when the drug is removed, the system overresponds to normal messenger levels.
Down-regulation: when messenger levels are chronically high, the cell removes or internalises receptors, becoming less sensitive. This contributes to drug tolerance.
Three variables determine how strongly a cell responds:
Messenger concentration: more messenger molecules means more receptors occupied.
Receptor density: more receptors on the surface means a greater chance of binding.
Receptor affinity: higher affinity means each receptor binds messenger more readily, even at low concentrations.
Agonists bind a receptor and activate it, producing the same effect as the natural messenger. Many drugs are receptor agonists.
Antagonists bind the receptor without activating it, blocking the natural messenger from binding. They reduce or prevent the response.
Clinical examples:
Antihistamines are antagonists at histamine receptors. Histamine (released by mast cells during inflammation) causes vasodilation and increased vascular permeability. Antihistamines block this, relieving allergy symptoms. First-generation antihistamines also block H1 receptors in the brain, causing drowsiness.
Beta-blockers (e.g. propranolol) are antagonists at β2-adrenergic receptors. They prevent epinephrine from binding, reducing heart rate and blood pressure.
Lipophilic messengers (steroid hormones, thyroid hormones) can cross the plasma membrane and bind receptors in the cytosol or nucleus.
The messenger enters the cell by diffusion.
It binds its intracellular receptor, forming a hormone-receptor complex.
The complex translocates to the nucleus (if it was not already there).
It binds hormone response elements (HREs) on DNA.
Gene transcription is turned up or down, changing the synthesis of specific proteins.
These responses are slower to start (minutes to hours, because new proteins must be synthesised) but longer-lasting than membrane receptor pathways.
These receptors are ion channels that open when a ligand binds.
Binding opens the channel, allowing specific ions (e.g. Ca²⁺, Na⁺, Cl⁻) to flow down their concentration gradient.
Effects include changes in membrane potential, muscle contraction, neurotransmitter release, enzyme activation.
Response is very fast (milliseconds) but brief, because the channel closes quickly after the ligand dissociates.
Example: calcium channels opening on ligand binding, allowing Ca²⁺ influx that triggers downstream events.
The most common enzyme-linked receptors are tyrosine kinase receptors.
Ligand binding causes the receptor to dimerise (two receptor molecules pair up).
The receptor autophosphorylates (adds phosphate groups to its own tyrosine residues).
Phosphorylated tyrosines serve as docking sites for intracellular signalling proteins.
This activates downstream cascades affecting metabolism, cell growth, and protein synthesis.
Many growth factors (e.g. insulin, EGF) signal through tyrosine kinase receptors.
GPCRs are the largest family of membrane receptors. They do not have intrinsic enzyme activity; instead, they activate separate G proteins inside the cell.
How the GPCR pathway works:
Ligand binds the GPCR on the extracellular side.
The receptor changes shape and activates a G protein on the intracellular side.
The G protein's alpha subunit exchanges GDP for GTP, becoming active.
The active G protein modulates an effector, which is either an enzyme (e.g. adenylate cyclase) or an ion channel.
The effector produces or regulates second messengers: cAMP, DAG, IP3, or Ca²⁺.
Second messengers relay the signal further, activating protein kinases and other downstream targets.
G protein subtypes:
Gs (stimulatory): activates adenylate cyclase → increases cAMP.
Gi (inhibitory): inhibits adenylate cyclase → decreases cAMP.
Gq: activates phospholipase C → produces DAG and IP3 → IP3 releases Ca²⁺ from the ER.
Example: β-adrenergic receptors bind epinephrine → activate Gs → adenylate cyclase produces cAMP → protein kinase A is activated → heart rate increases.
A single messenger molecule binding one receptor can produce a massive intracellular effect. Each step in the cascade multiplies the signal:
One ligand-receptor event activates several G proteins.
Each G protein activates one adenylate cyclase molecule.
Each adenylate cyclase produces many cAMP molecules.
Each cAMP molecule activates a protein kinase, which phosphorylates many target proteins.
The result: one extracellular messenger molecule can lead to thousands of intracellular product molecules. This is why tiny hormone concentrations can produce large physiological effects.
Clinical example: caffeine inhibits phosphodiesterase, the enzyme that breaks down cAMP. With PDE blocked, cAMP accumulates, prolonging and intensifying the signal. This is why caffeine increases alertness and heart rate.
Both systems use chemical messengers and receptors, but they differ in speed, duration, and reach.
Nervous system: neurotransmitters released at synapses; signals are fast (milliseconds), targeted to specific cells, and short-lived.
Endocrine system: hormones released into the bloodstream; signals are slower (seconds to hours), widespread, and longer-lasting. Many hormones signal via GPCRs or intracellular receptors, regulating gene expression and protein synthesis.
The two systems overlap: norepinephrine, for instance, acts as a neurotransmitter in the nervous system and as a hormone when released from the adrenal medulla.
Beta-blockers are among the most prescribed cardiovascular drugs. They work by antagonising β-adrenergic receptors, preventing epinephrine from increasing heart rate and blood pressure. Understanding GPCR signalling is also central to roughly 30–50% of all modern pharmaceuticals, since GPCRs are the target of a huge proportion of clinical drugs.
Students often think intracellular receptors respond faster than membrane receptors. The opposite is true: intracellular receptor pathways involve gene transcription and protein synthesis, so they are slower (but longer-lasting).
A common error is confusing second messengers with the receptors that produce them. cAMP is not a receptor; it is an intracellular molecule produced after the receptor has been activated.
Students sometimes assume that down-regulation means the receptor is broken. It is a normal, reversible regulatory mechanism.
Confusing agonist and antagonist is a perennial exam error. An agonist activates; an antagonist blocks.
⚠️ Be able to trace the full GPCR signalling cascade from ligand binding through G protein activation, effector modulation, second messenger production, and downstream response.
⚠️ Know the three main types of membrane receptors (channel-linked, enzyme-linked, GPCRs) and the speed/duration of each.
⚠️ Understand signal amplification and be able to explain why small amounts of messenger produce large effects.
⚠️ Up-regulation versus down-regulation, with direction of sensitivity change, is frequently tested.
⚠️ Agonist versus antagonist definitions plus clinical examples (antihistamines, beta-blockers) are common exam material.
⚠️ Caffeine's mechanism (PDE inhibition → cAMP accumulation) is a favourite exam question.
True or false: GPCRs have intrinsic enzyme activity.
A: False. GPCRs activate separate G proteins, which in turn modulate effector enzymes. The enzyme activity is on the effector, not the receptor.
Fill in the blank: The second messenger cAMP is produced by the enzyme __________ and broken down by the enzyme __________.
A: Adenylate cyclase; phosphodiesterase.
True or false: Down-regulation makes a cell more sensitive to a messenger.
A: False. Down-regulation reduces receptor numbers, making the cell less sensitive.
True or false: Intracellular receptors produce faster responses than ligand-gated ion channels.
A: False. Ligand-gated ion channels produce the fastest responses (milliseconds). Intracellular receptors produce slower responses because they require gene transcription and protein synthesis.
Fill in the blank: An __________ binds a receptor and activates it; an __________ binds a receptor and blocks it.
A: Agonist; antagonist.
Q: Trace the signal transduction pathway from epinephrine binding a β-adrenergic receptor to an increase in heart rate.
A: Epinephrine binds the β-adrenergic receptor (a GPCR) → the receptor activates a Gs protein → Gs activates adenylate cyclase → adenylate cyclase converts ATP to cAMP → cAMP activates protein kinase A → protein kinase A phosphorylates target proteins in the cardiac muscle cell → heart rate increases.
Q: A patient takes a beta-blocker. Explain, at the receptor level, why their heart rate decreases.
A: The beta-blocker is an antagonist at β-adrenergic receptors. It binds the receptor without activating it, preventing epinephrine from binding. Without epinephrine signalling through the GPCR-cAMP pathway, the stimulatory effect on heart rate is reduced.
Q: Explain how signal amplification allows a tiny amount of hormone to produce a large cellular effect.
A: Each step in the cascade multiplies the signal. One hormone molecule activates one receptor, which activates several G proteins. Each G protein activates an effector enzyme that produces many second messenger molecules. Each second messenger activates a kinase that phosphorylates many targets. The net result is an exponential increase from one extracellular molecule to thousands of intracellular responses.
Q: Compare the response time and duration of signalling through a ligand-gated ion channel versus an intracellular steroid receptor.
A: Ligand-gated ion channels respond in milliseconds (the channel opens immediately upon ligand binding) but the effect is brief because the channel closes quickly. Intracellular steroid receptors take minutes to hours to produce a response (the hormone-receptor complex must enter the nucleus, bind DNA, and alter gene transcription), but the effects last much longer because they involve changes in protein synthesis.
Q: A cell chronically exposed to high levels of insulin begins to show reduced responsiveness. What receptor-level mechanism explains this?
A: Down-regulation. The cell reduces the number of insulin receptors on its surface in response to the chronically elevated insulin levels, decreasing its sensitivity.
Signal transduction connects directly to the nervous system (synaptic transmission uses ligand-gated channels and GPCRs), the endocrine system (hormone signalling via GPCRs and intracellular receptors), and pharmacology (drug design targets agonists, antagonists, and enzymes in these pathways). The concept of signal amplification reappears in the blood clotting cascade and the complement system in immunology. Up-regulation and down-regulation are central to understanding drug tolerance and withdrawal.
signal transduction, receptor, GPCR, G protein-coupled receptor, G protein, Gs, Gi, Gq, second messenger, cAMP, cyclic AMP, DAG, IP3, calcium signalling, adenylate cyclase, phosphodiesterase, caffeine mechanism, signal amplification, phosphorylation cascade, protein kinase, tyrosine kinase receptor, enzyme-linked receptor, ligand-gated ion channel, channel-linked receptor, intracellular receptor, nuclear receptor, hormone response element, HRE, gene transcription, up-regulation, down-regulation, receptor affinity, receptor specificity, agonist, antagonist, beta-blocker, propranolol, antihistamine, histamine, nervous system vs endocrine system, membrane receptor, steroid receptor